Okano Y: Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am. 1996, 22: 709-735. 10.1016/S0889-857X(05)70297-0.
Article
CAS
PubMed
Google Scholar
Famularo G, Giacomelli R, Alesse E, Cifone MG, Morrone S, Boirivant M, Danese C, Perego MA, Santoni A, Tonietti G: Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol. 1989, 29: 59-63.
CAS
PubMed
Google Scholar
Sato S, Fujimoto M, Hasegawa M, Takehara K: Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 2004, 50: 1918-1927. 10.1002/art.20274.
Article
PubMed
Google Scholar
Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K: Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000, 165: 6635-6643.
Article
CAS
PubMed
Google Scholar
Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA. 2003, 100: 12319-12324. 10.1073/pnas.1635114100.
Article
PubMed Central
CAS
PubMed
Google Scholar
Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S: B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol. 2004, 165: 641-650.
Article
PubMed Central
CAS
PubMed
Google Scholar
Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002, 109: 1453-1462.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF: B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006, 169: 954-966. 10.2353/ajpath.2006.060205.
Article
PubMed Central
CAS
PubMed
Google Scholar
Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S: CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol. 2008, 172: 1650-1663. 10.2353/ajpath.2008.071049.
Article
PubMed Central
CAS
PubMed
Google Scholar
Novobrantseva I, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A: Attenuated liver fibrosis in the absence of B cells. J Clin Invest. 2005, 115: 3072-3082. 10.1172/JCI24798.
Article
PubMed Central
CAS
PubMed
Google Scholar
Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, De Pità O, Puddu P, Paganelli R, Russo G: Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004, 138: 540-546. 10.1111/j.1365-2249.2004.02642.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K: Serum levels of Interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol. 1998, 25: 308-316.
CAS
PubMed
Google Scholar
De Santis M, Bosello S, La Torre G, Capuano A, Tolusso B, Pagliari G, Pistelli R, Danza FM, Zoli A, Ferraccioli F: Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res. 2005, 6: 96-106. 10.1186/1465-9921-6-96.
Article
PubMed Central
PubMed
Google Scholar
Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG, Jimenez SA: In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology. 1993, 61: 239-246. 10.1159/000163802.
Article
CAS
PubMed
Google Scholar
Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K: Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol. 1998, 25: 296-301.
CAS
PubMed
Google Scholar
Kondo K, Okada T, Matsui T, Kato S, Date K, Yoshihara M, Nagata Y, Takagi H, Yoneda M, Sugie I: Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine. 2001, 13: 220-226. 10.1006/cyto.2000.0822.
Article
CAS
PubMed
Google Scholar
Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S: Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006, 54: 192-201. 10.1002/art.21526.
Article
CAS
PubMed
Google Scholar
Matsushita T, Fujimoto M, Hasegawa M, Matsushita Y, Komura K, Ogawa F, Watanabe R, Takehara K, Sato S: BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol. 2007, 127: 2772-2780.
CAS
PubMed
Google Scholar
Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010, 69: 193-197. 10.1136/ard.2008.095463.
Article
CAS
PubMed
Google Scholar
Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW: B cell depletion with Rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009, 60: 578-583. 10.1002/art.24249.
Article
PubMed Central
PubMed
Google Scholar
McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S: Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology. 2008, 47: 552-553. 10.1093/rheumatology/kem357.
Article
CAS
PubMed
Google Scholar
Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, Celik I: The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol. 2003, 22: 289-294. 10.1007/s10067-003-0733-2.
Article
CAS
PubMed
Google Scholar
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510.
Article
Google Scholar
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol. 1988, 15: 202-205.
CAS
PubMed
Google Scholar
Valentini G, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S: European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV: Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis. 2003, 62: 904-905. 10.1136/ard.62.9.904.
Article
PubMed Central
CAS
PubMed
Google Scholar
Valentini G, Silman AJ, Veale D: Assessment of disease activity. Clin Exp Rheumatol. 2003, 21 (Suppl 29): S39-S41.
CAS
PubMed
Google Scholar
Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W: Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003, 21 (Suppl 29): S42-S46.
PubMed
Google Scholar
Egan JJ, Martinez FJ, Wells AU, Williams T: Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005, 60: 270-273. 10.1136/thx.2004.035436.
Article
PubMed Central
CAS
PubMed
Google Scholar
Behr J, Furst DE: Pulmonary function tests. Rheumatol. 2008, 47 Suppl 5: v65-v67. 10.1093/rheumatology/ken313.
Article
CAS
Google Scholar
Kissin EY, Merkel PA, Lafyatis R: Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum. 2006, 54: 3655-3660. 10.1002/art.22186.
Article
PubMed
Google Scholar
Duncan MR, Berman B: Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol. 1991, 97: 686-692. 10.1111/1523-1747.ep12483971.
Article
CAS
PubMed
Google Scholar
Choi I, Kang HS, Yang Y, Pyun KH: IL-6 induces hepatic inflammation and collagen synthesis in vivo. Clin Exp Immunol. 1994, 95: 530-535.
Article
PubMed Central
CAS
PubMed
Google Scholar
Moodley YP, Misso NL, Scaffidi AK, Fogel-Petrovic M, McAnulty RJ, Laurent GJ, Thompson PJ, Knight DA: Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol. 2003, 29: 490-498. 10.1165/rcmb.2002-0262OC.
Article
CAS
PubMed
Google Scholar
Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P: BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren syndrome. Arthritis Rheum. 2007, 56: 1464-1477. 10.1002/art.22603.
Article
PubMed
Google Scholar
Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X: Increase of B cell-activating factor of the TNF family (BAFF) after Rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007, 66: 700-703. 10.1136/ard.2006.060772.
Article
PubMed Central
CAS
PubMed
Google Scholar